Granite Creek Copper Announces Participation in Ultramafic Technology Development Project Targeting the Star Property
The technology development project, entitled, 'Development of Extraction and Carbonation Technology for Ultramafic Rocks', is being led by Kemetco Research Inc. ('Kemetco'). The project will primarily focus on laboratory and pilot-scale development work for the technology aimed at enhanced metal extraction with a high level of carbon sequestration through carbonation of magnesium minerals.
Tim Johnson, President & CEO stated, 'The breadth of utility of ultramafic rocks continues to impress as exciting new technological advances and focus are brought to bear. Already prospective for nickel, copper, cobalt and platinum group metals the Star project can add carbon sequestration and geologic hydrogen production to the potential uses for the rocks found on site.'
About the Star Property
The Star project is located 190 kilometers northeast of Smithers, BC and is within 5 kilometers of the Omineca Resource Road and powerline that served the Kemess Mine. The 2500-hectare project is underlain by ultramafic rocks that are prospective for copper, nickel, cobalt, PGMs and gold as well as carbon sequestration and geologic hydrogen production.
Corporate Update
The Company also announces the departure of Chris Ackerman as VP Corporate Development. Mr. Ackerman has been a key member of the Granite Creek team since its original membership within the Metallic Group of Companies in 2019. The Company would like to thank Chris for his tireless dedication through difficult market conditions and wishes him the best in his future endeavors
About Granite Creek Copper
Granite Creek Copper is a focused on the exploration and development of critical minerals projects in North America and more recently on geologic hydrogen. The Company's projects consist of its flagship 177 square kilometer Carmacks project in the Minto copper district of Canada's Yukon Territory on trend with the formerly operating, high-grade Minto copper-gold mine and the advanced stage LS molybdenum project and the Star copper-nickel-PGM plus geological hydrogen project, both located in central British Columbia. Recent acquisitions include the Union Bay geologic hydrogen project as well as entering into a letter of intent to acquire the Duke Island ultramafic project for it's geologic hydrogen potential, both projects located in the state of Alaska. Granite Creek's goal is to be among the companies with first mover advantage in geologic hydrogen exploration by leveraging the considerable geological knowledge available to the company through its existing employee and consultant base plus the addition of key consultants with extensive knowledge in the field. More information about Granite Creek Copper can be viewed on the Company's website at www.gcxcopper.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Timothy Johnson, President & CEO
Telephone: 1 (604) 235-1982
Toll Free: 1 (888) 361-3494
E-mail: [email protected]
Qualified Person
Mr. Douglas Warkentin, P.Eng., a qualified person for the purposes of National Instrument 43-101, has reviewed and approved the technical information contained in this news release. Mr. Warkentin is a Senior Metallurgist with Kemetco Research and an advisor to the Company.
Forward-Looking Statements
Forward-Looking Statements: This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts including, without limitation, statements regarding potential mineralization, historic production, estimation of mineral resources, the realization of mineral resource estimates, interpretation of prior exploration and potential exploration results, the timing and success of exploration activities generally, the timing and results of future resource estimates, permitting time lines, metal prices and currency exchange rates, availability of capital, government regulation of exploration operations, environmental risks, reclamation, title, and future plans and objectives of the company are forward-looking statements that involve various risks and uncertainties. Although Granite Creek Copper believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same, and other exploration or other risks detailed herein and from time to time in the filings made by the companies with securities regulators. Readers are cautioned that mineral resources that are not mineral reserves do not have demonstrated economic viability. Mineral exploration and development of mines is an inherently risky business. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. For more information on Granite Creek Copper and the risks and challenges of their businesses, investors should review their annual filings that are available at www.sedar.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
13 minutes ago
- Miami Herald
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
-Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl-TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation-Company Strengthens Operational Leadership, Corporate Governance and Accounting RED BANK, NJ / ACCESS Newswire / August 4, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today issued a comprehensive corporate update highlighting significant advancements across its pipeline. The update underscores the rapid progression of TH104 as a lead asset addressing critical national security risks posed by weaponized fentanyl, and the transformative potential of TH023 in pioneering oral antibody delivery for widespread inflammatory conditions. The Company has strengthened its financial position by successfully completing several equity financings and securing approximately $5.47 million in gross proceeds before deducting placement and legal fees, during the latter part of the second quarter and continuing into the third quarter of this year. The capital infusion underscores the strong confidence from existing investors, whose continued commitment reflects a clear recognition of the Company's strategic vision and pipeline potential. We believe these proceeds will strategically accelerate the advancement of TH104, recognizing its paramount importance as a swiftly progressing national security asset, in addition to supporting general corporate purposes vital for the Company's continued growth and operational efficiency. "Over the past year, Tharimmune has achieved considerable milestones, particularly in advancing our lead candidate TH104 to a potential NDA with clear direction from FDA on a pathway while demonstrating preclinical success with our oral antibody program, TH023," stated Sireesh Appajosyula, Chief Executive Officer of Tharimmune. "Our strategic focus on high-impact solutions, from protecting military and first responders to redefining treatment paradigms for chronic inflammatory diseases, reflects our unwavering commitment to patient well-being and shareholder value." TH104: A National Security Solution Against Weaponized Fentanyl and High-Potency Opioids Tharimmune's lead asset, TH104, a buccal film formulation of nalmefene, has rapidly advanced with a regulatory pathway to address the escalating national security threat posed by weaponized fentanyl and other high-potency opioids like fentanyl. Addressing an Important National Security Threat: The U.S. government has increasingly recognized fentanyl and its related compounds as significant national security threats due to their extreme potency and potential for mass casualty incidents if weaponized. Incidents such as the 2002 Moscow theater hostage crisis, where aerosolized synthetic opioids were reportedly used, tragically demonstrated the devastating potential of such agents. In this critical context, Tharimmune explicitly positions TH104 as a direct response to this growing threat, aligning with the urgent need for specialized prophylactic medical countermeasures highlighted in recent U.S. Strategic National Stockpile (SNS) market assessments. Superiority and Convenience over Current Solutions: While existing solutions like naloxone auto-injectors are vital for emergency reversal, they often have a relatively short half-life (e.g., naloxone has a half-life of approximately 60-90 minutes to 2 hours). This can necessitate repeated dosing, particularly with longer-acting or highly potent synthetic opioids like fentanyl, which can have a significantly longer half-life (around 8 hours). TH104, which utilizes nalmefene, offers a crucial advantage with a significantly longer plasma half-life of approximately 8 to 11 hours. This extended duration of action means TH104 provides sustained protection, potentially reducing the need for continuous monitoring and potential multiple redosing in a high-risk environment. Furthermore, TH104's buccal film formulation allows for rapid and convenient administration, a critical benefit for military personnel and chemical incident responders who may be wearing full protective gear, where intramuscular injections can be impractical or delayed. Positive FDA Feedback and Expedited Pathway: In a pivotal development, Tharimmune previously announced positive feedback from the FDA regarding the New Drug Application (NDA) path for TH104. Crucially, the FDA confirmed that no additional clinical trials appear to be necessary prior to a 505(b)(2) NDA submission for TH104's proposed indication: "Temporary Prophylaxis of Respiratory and/or Nervous System Depression in Military Personnel and Chemical Incident Responders Entering an Area Contaminated with High-Potency Opioids." This expedited pathway allows Tharimmune to leverage existing extensive safety and efficacy data for nalmefene, combined with the Company's human pharmacokinetic data, enabling an "in silico" (computer simulation) submission model, significantly accelerating its potential availability. Robust Clinical Data and Metabolic Profile: Positive Phase 1 clinical data for TH104, presented at prominent conferences including Digestive Disease Week (DDW) and the European Association for the Study of the Liver (EASL) International Liver Congress in May 2025, highlights its distinct pharmacokinetic and metabolic profile. The data demonstrated that buccal administration achieves systemic exposure to nalmefene with reliable and predictable absorption and delayed phase 1 metabolism, potentially offering advantages for individuals with impaired liver function as potential added benefit. This scientific validation underpins TH104's suitability as a critical medical countermeasure. Strengthened Expertise in National Security: Tharimmune has strategically fortified its leadership to advance TH104's national security mission. James Gordon Liddy (CDR US Navy SEAL (Ret)), a renowned counter-terrorism and critical infrastructure expert, has been appointed to the Board of Directors and serves as a Key Strategic Advisor. His unparalleled expertise in national security and preparedness, including his role in designing and coordinating policy for the Global War on Terrorism and architecting the Navy's Anti-Terrorism Force Protection Plan, provides invaluable guidance for the development and potential deployment of TH104 within national security frameworks. The Promise of Oral Antibody Delivery The administration of monoclonal antibodies (mAb), while highly effective for a range of chronic diseases, has historically been limited to intravenous (IV) infusions or subcutaneous injections. These parenteral routes often necessitate frequent clinic visits, specialized medical personnel for administration, and can be painful or inconvenient for patients, impacting adherence to long-term therapy. The development of an effective oral delivery method for antibodies would truly be a "game-changer," revolutionizing patient access, convenience, and quality of life by transforming a complex, clinic-bound procedure into a simple, at-home pill. Overcoming the formidable physiological barriers of the gastrointestinal tract - including harsh pH environments, enzymatic degradation, and limited permeability for large molecules - has been a persistent challenge in biopharmaceutical development. We believe Tharimmune's TH023 program is at the forefront of addressing this critical unmet need. TH023: Pioneering Oral Antibody Delivery for Inflammatory Conditions Tharimmune is developing TH023, a novel oral monoclonal antibody targeting Tumor Necrosis Factor-alpha (TNF-alpha), licensed through Intract Pharma (UK), which could potentially revolutionize the delivery of biologic therapies for a wide array of inflammatory conditions. Preclinical Validation: In an advancement for oral antibody delivery, Tharimmune in the past year announced positive preclinical results for TH023. Leveraging a proprietary protease enzyme stabilized platform (Soteria®), preclinical studies in a murine model successfully demonstrated oral delivery of infliximab, achieving serum concentrations significantly higher than standard therapeutic levels. The studies confirmed enzymatic protection and successful in vivo delivery to both local colonic tissue and systemic circulation, highlighting its potential for treating both local gastrointestinal diseases (like Inflammatory Bowel Disease) and systemic inflammatory conditions. This proprietary formulation showed superior tissue penetration compared to traditional permeation enhancers, underscoring the innovative nature of TH023. Revolutionizing Patient Care and Market Potential: This program originated from a strategic global licensing agreement with Intract Pharma for INT-023 (now TH023) in September 2024. Traditionally, TNF-alpha inhibitors like infliximab (Remicade®) are administered via intravenous infusions or subcutaneous injections, which may be burdensome for patients. TH023 aims to overcome these challenges, offering a convenient oral pill form that could dramatically improve patient compliance, quality of life, and reduce healthcare system burdens. With the global infliximab market in the multibillions, an oral formulation represents a substantial commercial opportunity by providing a differentiated, patient-preferred option that broadens access and potentially lowers overall treatment costs. Future Development: Building on these promising preclinical results, Tharimmune plans to optimize TH023's formulation and dosing regimen and prepare for a first-in-human clinical trial within the next 12 months, marking a significant step towards bringing this transformative therapy to patients. Strengthening Corporate Governance and Leadership for Accelerated Growth Tharimmune has strategically enhanced its leadership and governance structure to support its ambitious pipeline advancements and future growth. Key Executive and Board Appointments: In addition to the strategic advisory role and Board appointment of James Gordon Liddy, Tharimmune has appointed Sireesh Appajosyula as Chief Executive Officer, leveraging his extensive experience in corporate development and operations. Vincent LoPriore, with decades of financial and investment banking experience, has been appointed Executive Chairman of the Board, further solidifying strategic oversight. The Board has also been strengthened by the appointments of Clay Kahler, bringing entrepreneurial leadership and expertise in life sciences manufacturing and clinical innovation, and Gary Stetz, a seasoned financial executive with extensive experience in accounting, finance, and corporate governance. These appointments collectively enhance the company's operational, financial, and strategic capabilities as it advances its critical programs. Tharimmune remains dedicated to leveraging its innovative platforms to address high unmet medical needs and drive significant value for patients and shareholders alike. About Tharimmune, Inc. Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contacts: Tharimmune, SOURCE: Tharimmune Inc.
Miami Herald
13 minutes ago
- Miami Herald
Inspire Veterinary Partners Announces up to $10M in Financing at $1.00 per Share Through Cash and Transferred Securities
VIRGINIA BEACH, VA / ACCESS Newswire / August 4, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today announced that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share. The gross proceeds to the Company from the offering are expected to be up to $10 million, including $6 million expected to be received through the investment of cash and securities at the first closing, and up to $4 million of cash that may be funded at one or more additional closings, at the election of the investors. The Company intends to use the net proceeds from the offering for general working capital and acquisitions of additional veterinary practices. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway. "As communicated earlier in 2025, the team at IVP is executing on our growth strategy and this offering helps to facilitate our objectives," said President, Chairman and CEO, Kimball Carr, "With new acquisitions onboarded and record clinical hiring this year, I could not be prouder of our team for the continued progress being made across all departments within IVP." This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Inspire Veterinary Partners, Inc. Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: Facebook | LinkedIn | X Forward-Looking Statements This press release contains forward-looking statements regarding the Company's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, statements by the Company relating to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, receipt of Stockholder Approval as well as risks and uncertainties related to the satisfaction of customary closing conditions related to anticipated acquisitions, or factors that result in changes to the Company's anticipated results of operations related to acquisitions. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact CoreIRMatt Blazei516-386-0430mattb@ Press Contact CORE IRMatthew Cosselpr@ General Inquires Morgan WoodMwood@ SOURCE: INSPIRE VETERINARY PARTNERS, INC.
Business Wire
13 minutes ago
- Business Wire
Priority Technology Holdings, Inc. Announces Closing of New Senior Credit Facilities with Lower Interest Rate
ALPHARETTA, Ga.--(BUSINESS WIRE)--Priority Technology Holdings, Inc. (NASDAQ: PRTH) ("Priority" or the "Company"), the payments and banking solution that streamlines collecting, storing, lending and sending money to unlock revenue opportunities, today announced the successful closing of $1.1 billion in new senior credit facilities, consisting of a $1 billion term loan with a 7-year maturity and a $100 million revolving credit facility with a 5-year maturity. The loan proceeds will be used to refinance existing debt, to satisfy outstanding obligations related to the 2023 acquisition of Plastiq, to fund strategic growth initiatives and for general corporate purposes. As a result of the financing, the Company lowered the interest rate on the term loan by 100 basis points compared to its existing debt and extended the term loan maturity to 2032. 'This significant refinancing strengthens our balance sheet, improves our cash flow and provides Priority with enhanced financial flexibility to execute our growth strategy,' said Tim O'Leary, Chief Financial Officer of Priority. 'The successful issuance of these credit facilities on favorable terms demonstrates the capital market's confidence in our business model and growth trajectory. We appreciate the strong support of both existing and new investors in this financing and look forward to continuing our focus on execution.' About Priority Priority is the payments and banking solution that enables businesses to collect, store, lend and send funds through a unified commerce engine. Our platform combines payables, merchant services, and banking and treasury solutions so leaders can streamline financial operations efficiently — and our innovative industry experts help businesses navigate and build momentum on the path to growth. With the Priority Commerce Engine, leaders can accelerate cash flow, optimize working capital, reduce unnecessary costs, and unlock new revenue opportunities. To learn more about Priority and its publicly traded parent, Priority Technology Holdings, Inc. (NASDAQ: PRTH), visit Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services, and other statements identified by words such as 'may,' 'will,' 'should,' 'anticipates,' 'believes,' 'expects,' 'plans,' 'future,' 'intends,' 'could,' 'estimate,' 'predict,' 'projects,' 'targeting,' 'potential' or 'contingent,' 'guidance,' 'outlook' or words of similar meaning. These forward-looking statements include, but are not limited to, the Purchase Agreement and our ability to close on the Purchase Agreement. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive risks, trends and uncertainties that could cause actual results to differ materially from those projected, expressed, or implied by such forward-looking statements. Our actual results could differ materially, and potentially adversely, from those discussed or implied herein. We caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this press release in the context of the risks and uncertainties disclosed in our SEC filings, including our most recent Annual Report on Form 10-K filed with the SEC on March 6, 2025. These filings are available online at or We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.
